AOPEP and Parkinson disease: A post hoc analysis of a Phase III study evaluated nausea and vomiting treatment-emergent adverse events in patients with PD who underwent SL-APO dose optimization (10–35 mg; 5-mg increments) to achieve a tolerable FULL ON.